Benefits of Cetalkonium Chloride Cationic Oil-in-water Nanoemulsions for Topical Ophthalmic Drug Delivery

Overview

Journal J Pharm Pharmacol

Publisher Oxford University Press

Specialties Pharmacology
Pharmacy

Date 2013 Sep 5

PMID 24001405

Citations 33

Authors

Philippe Daull

Frederic Lallemand

Jean-Sebastien Garrigue

Affiliations

Soon will be listed here.

Abstract

Objectives: Topical ocular administration is the most convenient route of administration of drugs for the treatment of eye diseases. However, the bioavailability of drugs following eye instillations of eye drops is very low. Over the past 20 years, extensive efforts have been put into research to improve drug bioavailability without compromising treatment compliance and patients' quality of life.

Key Findings: One of the most efficient ways to improve drug bioavailability is to increase the precorneal residence time of the eye drop formulations. As a result, new eye drops, with bioadhesive properties, have been developed based on the cationic oil-in-water (o/w) nanoemulsion technology. These low viscosity eye drop nanoemulsions have improved precorneal residence time through the electrostatic interactions between the positively charged oil nanodroplets and the negatively charged ocular surface epithelium.

Summary: This review is the first to present the benefits of this new strategy used to improve ocular drug bioavailability. The roles of the cationic agent in the stabilization of a safe cationic o/w nanoemulsion have been discussed, as well as the unexpected benefits of the cationic o/w nanoemulsion for the protection and restoration of a healthy tear film and corneal epithelium.

Citing Articles

A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.

Baudouin C, Stalmans I, Bourne R, Larrosa J, Schmickler S, Seleznev A Eye (Lond). 2025; .

PMID: 40000909 DOI: 10.1038/s41433-025-03646-z.

Clinical efficacy of 0.1% cyclosporine A in dry eye patients with inadequate responses to 0.05% cyclosporine A: a switching, prospective, open-label, multicenter study.

Yoon S, Kim E, You I, Choi C, Kim J, Song J BMC Ophthalmol. 2025; 25(1):37.

PMID: 39844141 PMC: 11752847. DOI: 10.1186/s12886-025-03862-x.

Simvastatin is delivered to the brain by high-strength intranasal cationic SMEDDS and nanoemulsions.

Gama F, Meirinho S, Pires P, Tinoco J, Martins Gaspar M, Baltazar G Drug Deliv Transl Res. 2025; .

PMID: 39747745 DOI: 10.1007/s13346-024-01769-6.

Recent Advances in Nanotechnology for the Treatment of Dry Eye Disease.

Coco G, Buffon G, Taloni A, Giannaccare G Nanomaterials (Basel). 2024; 14(8).

PMID: 38668163 PMC: 11053557. DOI: 10.3390/nano14080669.

Recent progress of nanomedicine in managing dry eye disease.

Lv Z, Li S, Zeng G, Yao K, Han H Adv Ophthalmol Pract Res. 2024; 4(1):23-31.

PMID: 38356795 PMC: 10864857. DOI: 10.1016/j.aopr.2024.01.008.

References

Klang S, Frucht-Pery J, Hoffman A, Benita S . Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J Pharm Pharmacol. 1994; 46(12):986-93. DOI: 10.1111/j.2042-7158.1994.tb03254.x. View

Urtti A . Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006; 58(11):1131-5. DOI: 10.1016/j.addr.2006.07.027. View

Daull P, Buggage R, LAmbert G, Faure M, Serle J, Wang R . A comparative study of a preservative-free latanoprost cationic emulsion (Catioprost) and a BAK-preserved latanoprost solution in animal models. J Ocul Pharmacol Ther. 2012; 28(5):515-23. DOI: 10.1089/jop.2011.0245. View

Smith M, Flowers T, Cowling M, Duncan H . Method for the measurement of the diffusion coefficient of benzalkonium chloride. Water Res. 2002; 36(6):1423-8. DOI: 10.1016/s0043-1354(01)00356-6. View

Furrer P, Mayer J, Gurny R . Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm. 2002; 53(3):263-80. DOI: 10.1016/s0939-6411(01)00246-6. View

Lallemand F, Daull P, Benita S, Buggage R, Garrigue J . Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012; 2012:604204. PMC: 3313063. DOI: 10.1155/2012/604204. View

Abdelkader H, Alany R . Controlled and continuous release ocular drug delivery systems: pros and cons. Curr Drug Deliv. 2012; 9(4):421-30. DOI: 10.2174/156720112801323125. View

Ammar D, Noecker R, Kahook M . Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010; 27(11):837-45. DOI: 10.1007/s12325-010-0070-1. View

Liang H, Brignole-Baudouin F, Rabinovich-Guilatt L, Mao Z, Riancho L, Faure M . Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol Vis. 2008; 14:204-16. PMC: 2254971. View

10.

Li D, Chen Z, Song X, Luo L, Pflugfelder S . Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2004; 45(12):4302-11. DOI: 10.1167/iovs.04-0299. View

11.

Rabinovich-Guilatt L, Couvreur P, LAmbert G, Dubernet C . Cationic vectors in ocular drug delivery. J Drug Target. 2004; 12(9-10):623-33. DOI: 10.1080/10611860400015910. View

12.

Liang H, Baudouin C, Faure M, LAmbert G, Brignole-Baudouin F . Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis. 2009; 15:1690-9. PMC: 2731833. View

13.

Daull P, Lallemand F, Philips B, LAmbert G, Buggage R, Garrigue J . Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2012; 32(3):345-54. DOI: 10.1097/ICO.0b013e31825e83f4. View

14.

Liang H, Baudouin C, Daull P, Garrigue J, Brignole-Baudouin F . Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model. Mol Vis. 2012; 18:2195-204. PMC: 3425577. View

15.

du Toit L, Pillay V, Choonara Y, Govender T, Carmichael T . Ocular drug delivery - a look towards nanobioadhesives. Expert Opin Drug Deliv. 2010; 8(1):71-94. DOI: 10.1517/17425247.2011.542142. View

16.

Kahook M, Ammar D . In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells. J Ocul Pharmacol Ther. 2010; 26(3):259-63. DOI: 10.1089/jop.2010.0003. View

17.

Daull P, Feraille L, Elena P, Garrigue J . Comparison of the Anti-Inflammatory Effects of Artificial Tears in a Rat Model of Corneal Scraping. J Ocul Pharmacol Ther. 2016; 32(2):109-18. PMC: 4779975. DOI: 10.1089/jop.2015.0054. View

18.

Vandamme T . Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002; 21(1):15-34. DOI: 10.1016/s1350-9462(01)00017-9. View

19.

Baudouin C, de Lunardo C . Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998; 82(1):39-42. PMC: 1722345. DOI: 10.1136/bjo.82.1.39. View

20.

Rubino J . The influence of charged lipids on the flocculation and coalescence of oil-in-water emulsions. I: Kinetic assessment of emulsion stability. J Parenter Sci Technol. 1990; 44(4):210-5. View